Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
| ▸ | MPO | P05164 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | RAD52 | P43351 | 2/20 | 0.31 |
| ▸ | RECQL | P46063 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.31 |
| ▸ | GAPDH | P04406 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6284487 | 0.82 | TAAR1 (0.44) | MPOTAAR1MEN1RAD52RECQL | |
| SCHEMBL13068796 | 0.80 | LOXL2 (0.34) | LOXL2TAAR1 | |
| Hydrochloric Acid SCHEMBL12818395 | 0.80 | KMT2A (0.46) | MPOTAAR1MEN1RAD52RECQL | |
| SCHEMBL13083063 | 0.78 | LOXL2 (0.33) | LOXL2DPP4 | |
| SCHEMBL13527770 | 0.77 | LOXL2 (0.42) | LOXL2MPOTAAR1MEN1RAD52 | |
| SCHEMBL31346729 | 0.77 | LOXL2 (0.42) | LOXL2MPOTAAR1MEN1RAD52 | |
| SCHEMBL29661802 | 0.77 | TAAR1 (0.30) | TAAR1MEN1RAD52RECQLKMT2A | |
| SCHEMBL855027 | 0.77 | RIPK1 (0.41) | LOXL2MPODPP4 | |
| SCHEMBL6283815 | 0.77 | MPO (0.41) | MPOTAAR1 | |
| SCHEMBL9355053 | 0.76 | HDAC3 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210052736-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | APOSENSE LTD (IL) | 2021-02-25 | — | — | US | claimed |
| EP-3735276-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | Aposense Ltd. (IL) | 2020-11-11 | — | — | EP | claimed |
| US-12337036-B2 | Compounds and methods for trans-membrane delivery of molecules | APOSENSE LTD (IL) | 2025-06-24 | — | — | US | disclosed |
| US-20210052736-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | APOSENSE LTD (IL) | 2021-02-25 | — | — | US | disclosed |
| EP-3735276-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | Aposense Ltd. (IL) | 2020-11-11 | — | — | EP | disclosed |
| EP-2037951-A2 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | Sirion Therapeutics, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007150046-A2 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | SIRION THERAPEUTICS, INC (US) | 2007-12-27 | — | — | WO | disclosed |
| US-6452056-B1 | REDUCING FLUORINATED BENZONITRILE TO A BENZYLAMINE WHICH IS REPLACED WITH A HYDROXYL GROUP | ASAHI GLASS COMPANY, LIMITED (JP) | 2002-09-17 | — | — | US | disclosed |
| CN-1312783-A | Process for preparing fluorobenzyl derivatives | ASASHI GLASS CO (JP) | 2001-09-12 | — | — | CN | disclosed |
| EP-1114809-A1 | PROCESS FOR THE PREPARATION OF FLUOROBENZYL DERIVATIVES | Asahi Glass Co., Ltd. (JP) | 2001-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12337036-B2 | Compounds and methods for trans-membrane delivery of molecules | LDLR, NPC1L1, ABCB4 | LOXL2 489/4885MPO 3369/4885TAAR1 2865/4885 |
| US-20210052736-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | LDLR, NPC1L1, ABCB4 | LOXL2 489/4885MPO 3369/4885TAAR1 2865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.